

Reference:	FOI.3293.20
Subject:	Non-small-cell lung cancer
Date of Request:	5 June 2020

Requested:

1. Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:

- Afatinib
- Atezolizumab monotherapy or combination
- Brigatinib
- Ceritinib
- Crizotinib
- Docetaxel mono or combination
- Erlotinib
- Gefitinib
- Gemcitabine
- Nitendanib + docetaxel
- Nivolumab
- Osimertinib
- Paclitaxel
- Pembrolizumab monotherapy
- Pembrolizumab chemo in combination
- Pembrolizumab monotherapy
- Pemetrexed monotherapy of combination with Carboplatin/Cisplatin
- Ramucirumab
- Vinorelbine mono or combination
- Other active systemic anti-cancer therapy
- Palliative care only

2. Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC) with the following products?

- Afatinib
- Atezolizumab monotherapy or combination
- Brigatinib
- Ceritinib
- Crizotinib
- Docetaxel mono or combination
- Erlotinib
- Gefitinib
- Gemcitabine
- Nitendanib + docetaxel
- Nivolumab
- Osimertinib
- Paclitaxel
- Pembrolizumab monotherapy
- Pembrolizumab chemo in combination
- Pembrolizumab monotherapy

Pemetrexed monotherapy of combination with Carboplatin/Cisplatin
Ramucirumab
Vinorelbine mono or combination
Other active systemic anti-cancer therapy
Palliative care only

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the number of patients currently being treated with the above named therapies, as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The ChemoCare team, who hold a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients’ medical records to establish the type of therapies being used to treat the patients. It is estimated that conducting this search would take longer than the 18 hour ‘appropriate limit’ as stated within the Act.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

Under section 16 of the Freedom of Information Act, the UHB has an obligation to provide advice and assistance.

We would therefore recommend that you redirect your request to the Freedom of Information Team in SBUHB who may be able to help you with your enquiry:-

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.